Next Investors logo grey

News from the world of biotech

Published 03-SEP-2018 11:27 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Growing up, I never had any real interest in science or technology.

(A bit rich coming from the person bringing you this biotech-themed newsletter I admit, but it’s true.)

I was never any good at maths. And physics — forget about it.

I did have a passing interest in biology, but that was short-lived after a chemical mix up sent a spark from the test tube down the front of my school shirt, incinerating the birthmark on my chest. I don’t know if that says more about my inability as a scientist, or the lack of safety in schools in the 1980s.

Probably a bit of both. But I digress...

What I have developed as time has gone by is an interest in research and development for various cancers. Cancer has taken the lives of several family friends and I have a young niece currently in remission.

Heart disease and diabetes also run in the family. So I keep a keen eye on any progress made by biotech and medtech companies with regards to potential cures and preventions for a whole range of conditions.

Some of those companies have already featured heavily in Finfeed and include Respiri, Prescient (see below), Neurotech, Immuron, Rhythm Biosciences and more.

Medical diagnostics innovator Rhythm Biosciences is in the process of preparing reagents for its ColoSTATTM blood test, which tests for colorectal cancer. Prescient Therapeutics is working in the field of breast cancer, bringing two novel cancer drugs to the table.

As we move forward to cover a broader church in this space on Finfeed, some of the companies will be ASX listed entities; others will be unlisted companies (which may not be suitable for retail investors) working for the greater good to eradicate various diseases.

We’ll also take a look at what’s happening in the various sectors that make up the biotech landscape including agricultural biotechnology, plant biotechnology, nutrient, industrial and more... and we’ll link you to articles such as How Plant Biotechnology Can Give Us Better Food and Medicines.

The importance of being Biotech

Put simply, biotech is technology based on biology. The highschool kid in me shudders at the thought. The adult in me says No, no — keep going. I want to hear more about it.

Here's another definition from USC News: “Biotech uses the cellular and molecular processes that occur in living organisms to create products that treat diseases, improve agriculture and reduce our environmental footprint.

“Modern biotechnology provides breakthrough products and technologies to combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes.” (Read the full USC article here.)

The importance of biotech shouldn’t be underestimated, considering it can lead to tailor-made cures, eradication of diseases, better diagnostics and an overall healthier society.

(Maybe it could even regenerate my birthmark. A man can hope!)

I'm looking forward to bringing you a weekly rundown of my findings and thoughts on this exciting sector — so stay tuned.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.